Given the differences between HER2 expression in breast and gastric cancer, a different HER2 scoring system was developed and validated for gastric adenocarcinoma by Hofmann et al. [12] for the TOGA trial [13]. The gene discussed is ERBB2; the disease is gastric adenocarcinoma.